September 5, 2024 11:11 AM EDT
News Briefing

No­var­tis pays $15M up­front to li­cense Voy­ager pro­gram; Boehringer ad­vances ge­o­graph­ic at­ro­phy drug

ENDPOINTS

Plus, news about Jnana Ther­a­peu­tics, Vax­cyte, C-Fur­ther, Gen­prex, Phar­maEssen­tia, FORUS Ther­a­peu­tics, Phar­ma Two B and He­p­i­on:

No­var­tis li­cens­es Voy­ager pro­gram: Voy­ager will get $15 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Scor­pi­on de­tails ear­ly da­ta on tar­get­ed breast can­cer drug as it seeks to chal­lenge No­var­tis, Roche

Ar­bor Biotech­nolo­gies cuts ear­ly-stage dis­cov­ery work, lays off staff

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

FDA ap­proves sub­cu­ta­neous Ocre­vus, broad­en­ing ac­cess to Roche and Genen­tech block­buster

Up­dat­ed: Bris­tol My­ers touts LAG-3 strat­e­gy in lung can­cer, but da­ta caveats damp­en ex­cite­ment

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

A service from the Financial Times